Impact of aspiration catheter inner diameter on first-pass effect: A systematic review and meta-analysis.

Interv NeuroradiolJun 10, 2025 (epub)
Clinical ResearchNeurologyOpen access

Seyed Behnam Jazayeri, Abdullah Reda, Jonathan Cortese et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined whether distal inner diameter of contact aspiration catheters was associated with first-pass revascularization during mechanical thrombectomy. Across 34 articles involving 4,831 patients, pooled first-pass effect (TICI 2c–3) rates were 27.7% for medium-bore, 46.6% for large-bore, and 58.3% for super-large-bore catheters. The rate was significantly higher with super-large-bore catheters than with the other groups (χ² = 7.26, p = 0.03). Modified first-pass effect rates showed a similar pattern, but the findings indicate association rather than causation.

Key findings

  • First-pass effect rates were 27.7% (95% CI, 15.1-45.3) for medium-bore, 46.6% (95% CI, 33.7-59.9) for large-bore, and 58.3% (95% CI, 44.8-70.7) for super-large-bore catheters.
  • Super-large-bore catheters had significantly higher first-pass effect rates than the other groups (χ² = 7.26, p = 0.03).
  • Modified first-pass effect rates were 51.1% for medium-bore, 60.0% for large-bore, and 80% for super-large-bore catheters (χ² = 8.14, p = 0.03).

Why it matters

Achieving substantial revascularization in one thrombectomy pass is a clinically relevant procedural outcome. The pooled results suggest catheter inner diameter may be associated with the likelihood of first-pass success, providing comparative evidence that can inform evaluation of aspiration-device strategies. Because the analysis synthesizes reported studies rather than testing catheter sizes in a randomized comparison, the observed differences should not be interpreted as proof that larger catheters cause better outcomes.

What to keep in mind

The analysis pooled results from 34 articles; the abstract does not report a randomized comparison of catheter sizes, so differences may reflect factors beyond catheter diameter.

Source

Published in Interv Neuroradiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.